These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19874983)

  • 1. [New therapeutic agents in immunologic idiopathic thrombocytopenic purpura treatment: thrombopoietin receptor agonists].
    Khellaf M
    Rev Med Interne; 2009 Oct; 30(9 Suppl):13-5. PubMed ID: 19874983
    [No Abstract]   [Full Text] [Related]  

  • 2. Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.
    Al-Nawakil C; Park S; Chapuis N; Dreyfus F; Szwebel TA; Gibault L; Molina T; Hermine O; Bouscary D; Tamburini J
    Br J Haematol; 2012 Jan; 156(1):145-7. PubMed ID: 21848881
    [No Abstract]   [Full Text] [Related]  

  • 3. Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura.
    Gardiner EE; Thom JY; Al-Tamimi M; Hughes A; Berndt MC; Andrews RK; Baker RI
    Br J Haematol; 2010 May; 149(4):625-8. PubMed ID: 20148887
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
    Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
    J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
    [No Abstract]   [Full Text] [Related]  

  • 5. The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
    Veneri D; Soligo L; Pizzolo G; Ambrosetti A
    Blood Transfus; 2015 Oct; 13(4):694-5. PubMed ID: 26057496
    [No Abstract]   [Full Text] [Related]  

  • 6. Idiopathic thrombocytopenic purpura: advances in management.
    Neunert C
    Clin Adv Hematol Oncol; 2011 May; 9(5):404-6. PubMed ID: 21685870
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of chronic immune thrombocytopenia in children with romiplostim.
    Chaturvedi S; McCrae KR
    Lancet; 2016 Jul; 388(10039):4-6. PubMed ID: 27103125
    [No Abstract]   [Full Text] [Related]  

  • 8. ITP, interrupted.
    Stasi R
    Blood; 2011 Oct; 118(16):4297-8. PubMed ID: 22021448
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
    Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
    [No Abstract]   [Full Text] [Related]  

  • 10. [Development of thrombopoietin receptor agonists].
    Miyakawa Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
    [No Abstract]   [Full Text] [Related]  

  • 11. [Management of refractory ITP with thrombopoietin receptor agonists].
    Tomiyama Y
    Rinsho Ketsueki; 2011 Aug; 52(8):627-32. PubMed ID: 21897068
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
    Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
    Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
    [No Abstract]   [Full Text] [Related]  

  • 13. New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
    Francesco R
    Eur J Haematol Suppl; 2009 Mar; (71):1-2. PubMed ID: 19200300
    [No Abstract]   [Full Text] [Related]  

  • 14. Thrombopoiesis: new ITP paradigm?
    Despotovic JM; Ware RE
    Blood; 2011 Jul; 118(1):1-2. PubMed ID: 21737604
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia.
    Mahat U; Talati R; Kodish E
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27706. PubMed ID: 30854752
    [No Abstract]   [Full Text] [Related]  

  • 16. Remissions after long-term use of romiplostim for immune thrombocytopenia.
    Marshall AL; Scarpone R; De Greef M; Bird R; Kuter DJ
    Haematologica; 2016 Dec; 101(12):e476-e478. PubMed ID: 27587382
    [No Abstract]   [Full Text] [Related]  

  • 17. Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.
    Raval JS; Redner RL; Kiss JE
    J Clin Apher; 2013 Aug; 28(4):321-4. PubMed ID: 23450778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
    Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
    Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
    [No Abstract]   [Full Text] [Related]  

  • 19. What is publication? The case of eltrombopag.
    Benham L; Guo L; Turner R
    Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacological and clinical profile of romiplostim (Romiplate(®) 250 µg for s.c. injection)].
    Furuya Y; Ishii H; Aono Y; Arai Y; Onda F; Hasegawa K; Yanagida M
    Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):34-9. PubMed ID: 21747207
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.